AZTA Jul 2024 85.000 call
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 85.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
PR NewswireAzenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn's disease and ulcerative colitis. Azenta will provide sample management services, including sample processing, analysis, logistics, and storage for these pivotal studies.
- PR Newswire
Azenta to Participate in the Jefferies Global Healthcare Conference
Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.
PR NewswireAzenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market. The new laboratory brings Azenta closer to UK-based researchers, providing advanced next-generation sequencing (NGS) platforms and a local team of top-tier scientists from Oxford.
